Literature DB >> 1071666

Anti-hypertensive effect of acebutolol: its relation to sympathetic nervous system responsiveness and to plasma renin and dopamine-beta-hydroxylase activities.

A Fournier, J M Hardin, J M Alexandre, M Lombaert, G Ronco, J F Bezoc, G Desmet, J Quichaud.   

Abstract

1. Acebutolol, a beta1-receptor blocker, has, at a daily dose of 800 mg, a mild but significant anti-hypertensive effect in moderate sustained essential hypertension with normal or low plasma renin activity. 2. Prediction of its anti-hypertensive effect is better based on the evaluation of the sympathetic nervous system responsiveness to head-up tilt than on the evaluation of plasma renin activity or dopamine-beta-hydroxylase. 3. The anti-hypertensive effect of acebutolol is better explained on the basis of inhibition of the sympathetic nervous system activity than on the basis of suppression of plasma renin activity. 4. A positive correlation between plasma renin activity and dopamine-beta-hydroxylase in patients on diuretics suggests the common dependence of these two variables on sympathetic overactivity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1071666     DOI: 10.1042/cs051477s

Source DB:  PubMed          Journal:  Clin Sci Mol Med Suppl        ISSN: 0144-4107


  5 in total

Review 1.  The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

2.  Acebutolol in hypertension: relationships between drug concentration and effects.

Authors:  M A Martin; F C Phillips; G T Tucker; A J Smith
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

3.  Propranolol and beta-adrenergic receptor blocking drugs in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1982-01       Impact factor: 4.335

4.  Effect of propranolol on noradrenaline kinetics in patients with essential hypertension.

Authors:  M Esler; G Jackman; P Leonard; H Skews; A Bobik; G Jennings
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

5.  Acebutolol in hypertension--double-blind trial against placebo.

Authors:  M A Martin; C A Phillips; A J Smith
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.